CN106883185B - Preparation method of 4-chloro-2-trifluoromethylpyrimidine - Google Patents

Preparation method of 4-chloro-2-trifluoromethylpyrimidine Download PDF

Info

Publication number
CN106883185B
CN106883185B CN201510935307.5A CN201510935307A CN106883185B CN 106883185 B CN106883185 B CN 106883185B CN 201510935307 A CN201510935307 A CN 201510935307A CN 106883185 B CN106883185 B CN 106883185B
Authority
CN
China
Prior art keywords
compound
formula
sodium methoxide
reaction
process according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201510935307.5A
Other languages
Chinese (zh)
Other versions
CN106883185A (en
Inventor
杨耀宇
张飞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PORTON FINE CHEMICALS Ltd
Original Assignee
PORTON FINE CHEMICALS Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PORTON FINE CHEMICALS Ltd filed Critical PORTON FINE CHEMICALS Ltd
Priority to CN201510935307.5A priority Critical patent/CN106883185B/en
Publication of CN106883185A publication Critical patent/CN106883185A/en
Application granted granted Critical
Publication of CN106883185B publication Critical patent/CN106883185B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30Halogen atoms or nitro radicals

Abstract

The invention discloses a preparation method of 4-chloro-2-trifluoromethylpyrimidine (formula I), which is prepared by taking methyl trifluoroacetate and malonamide which are low in price and easy to purchase as raw materials.The method does not use expensive materials, has mild reaction conditions, simple equipment, low EHS risk and low cost, and is suitable for large-scale production.

Description

Preparation method of 4-chloro-2-trifluoromethylpyrimidine
Technical Field
The invention belongs to the field of pharmaceutical chemicals, and particularly relates to a preparation method of an active drug intermediate for treating diseases related to arteriosclerosis, nephropathy, tumors, cardiovascular diseases, anxiety, depression and the like.
Background
4-chloro-2-trifluoromethylpyrimidine is an important medical intermediate, and the preparation methods reported at present are few. Among them, the target compound is obtained by cyclization with ethyl 3-oxopropionate using trifluoroacetamidine and ethyl trifluoroacetamidine as reported in document j, org, chem, 26, 4505, 1961, as shown in the following reaction scheme:
Figure 8581DEST_PATH_IMAGE002
however, both the raw materials of the trifluoroacetamidine and the ethyl 3-oxopropionate do not have a large number of suppliers at home, and the synthesis of the trifluoroacetamidine is reported to be mainly obtained by the high-pressure reaction of trifluoroacetonitrile and ammonia gas, wherein the boiling point of the trifluoroacetonitrile is only-65 ℃, and the trifluoroacetonitrile belongs to a low-boiling-point high-toxicity substance and also has no large number of suppliers. The limitations of the starting materials make the synthesis of this compound difficult and the development of new synthetic methods very promising.
Disclosure of Invention
The invention discloses a preparation method of 4-chloro-2-trifluoromethylpyrimidine (formula I), which is prepared by taking methyl trifluoroacetate and malonamide which are low in price and easy to purchase as raw materials. The method does not use expensive materials, has mild reaction conditions, simple equipment, low EHS risk and low cost, and is suitable for large-scale production.
1. The invention discloses a preparation method of a compound shown in a formula I,
Figure 275614DEST_PATH_IMAGE003
the method comprises the following steps:
a) reacting the compound shown in the formula V with sodium methoxide to prepare a reaction solution containing the compound shown in the formula IV; carrying out catalytic hydrogenation on a reaction liquid containing a compound shown in a formula IV to prepare a compound shown in a formula III; the method does not need to separate and purify the compound of the formula IV, and obtains the compound of the formula III by feeding the compound of the formula V in a one-pot method.
Figure 474514DEST_PATH_IMAGE004
b) The compound of the formula III is subjected to demethylation reaction to prepare a compound of a formula II;
Figure 674552DEST_PATH_IMAGE005
c) halogenating the compound of formula II in the presence of a halogenating agent to produce the compound of formula I.
2. The process as described in 1, step a) should be strictly controlled in the amount of sodium methoxide, otherwise both chlorides will be substituted by methoxy groups, the molar ratio of the amounts of sodium methoxide and compound of formula V being: 1.15-1: 1.
3. In the process according to claim 2, the molar ratio of the amounts of sodium methoxide and compound of formula V is preferably: 1.05:1.
4. The process as described in 1, the catalyst used for the catalytic hydrogenation in step a) being Pd/C.
5. The process as described in 1, the reagent used for the demethylation reaction in step b) is hydrobromic acid.
6. The process as described in 1, the halogenating agent in step c) being POCl 3.
7. The method as described in 1, wherein the compound of formula V is prepared by the following method, which is characterized by comprising the following steps:
d) preparing a compound VI from a compound shown in a formula VII and methyl trifluoroacetate in the presence of a condensing agent;
Figure 667915DEST_PATH_IMAGE006
e) reacting the compound VI with a halogenating agent to prepare a compound V;
Figure 828770DEST_PATH_IMAGE007
8. the process according to 7, wherein the condensing agent in step d) is sodium methoxide.
9. The method as described in 8, wherein the molar ratio of the sodium methoxide to the compound of formula VII is 2-3: 1.
10. In the process according to claim 9, the molar ratio of sodium methoxide to VII compound is preferably 2.2: 1.
11. The process as described in 7, the halogenating agent in step e) being POCl 3.
12. In the method of 7, triethylamine is required to be added as a base in the step e), and the triethylamine can accelerate the reaction to complete the reaction.
The specific implementation mode is as follows:
EXAMPLE 1 preparation of 2-trifluoromethyl-4, 6-dihydroxypyrimidine (VI)
Adding 500 mL of methanol into a reaction bottle, cooling to 0-5 ℃, adding 118.6 g of sodium methoxide, stirring until the mixture is basically clear, adding 102.1g of malonamide, stirring, heating to 35 ℃, adding 153.7g of methyl trifluoroacetate, stirring for 30 minutes after the addition is finished, and heating to 65-70 ℃ for refluxing for 15 hours. After the reaction is finished, cooling to 25-35 ℃, dropwise adding 100 mL of methyl tert-ether, cooling to 5-10 ℃ after dropwise adding, stirring, filtering, leaching a filter cake with methyl tert-ether, transferring the solid to a single-mouth bottle after filtering, and concentrating under reduced pressure. Adding water, stirring until the mixture is clear, adding concentrated hydrochloric acid to adjust the pH = 1-2, and filtering to obtain 95g of a filter cake. And adding 250 mL of ethyl acetate into the filter cake, heating to reflux, stirring, filtering, and concentrating under reduced pressure to constant weight to obtain 118.4g of off-white solid, wherein the yield is 65.8 percent and the HPLC is 94.3 percent.
EXAMPLE 2 preparation of 4, 6-dichloro-2-trifluoromethylpyrimidine (V)
Adding 144.1 g of phosphorus oxychloride into a reaction bottle, stirring, adding 36g of 2-trifluoromethyl-4, 6-dihydroxypyrimidine, stirring, cooling to 5-10 ℃, dropwise adding 55.4 mL of triethylamine, heating to 100-105 ℃ after dropwise addition, reacting for 4 hours, controlling the temperature to be 0-5 ℃ after the medium-controlled reaction is qualified, adding the reaction solution into ice water, stirring, adding dichloromethane, stirring for layering, adding dichloromethane into the water phase, extracting, combining organic phases, washing, filtering, and drying to obtain a crude product. The crude product was distilled and the product distilled off was collected as a colorless liquid 31.4g, yield 72.4%, HPLC 99.9%.
EXAMPLE 3 preparation of 4-methoxy-2-trifluoromethylpyrimidine (III)
Adding 100 mL of methanol into a reaction bottle, cooling to 0-5 ℃, adding 7.8 g of sodium methoxide in batches, and stirring for 10 minutes until the sodium methoxide is basically dissolved and clear for later use. And then adding 100 mL of methanol and 27.2 g of 4, 6-dichloro-2-trifluoromethylpyrimidine into another reaction bottle, dropwise adding the prepared sodium methoxide methanol solution at 10-20 ℃, stirring for 5 hours at 30-35 ℃, filtering the reaction solution after the raw materials react, leaching a filter cake with 50 mL of methanol, and combining the filtrates to obtain the 4-chloro-6-methoxy-2-trifluoromethylpyrimidine solution.
And (2) adding 2 g of 10% palladium carbon and 14 g of triethylamine into the 4-chloro-6-methoxy-2-trifluoromethylpyrimidine solution obtained in the previous step, replacing with nitrogen, introducing hydrogen under normal pressure, stirring for 15 hours at 25-35 ℃, controlling the reaction to be finished, filtering the reaction solution, and leaching a filter cake with 50 mL of methanol. The filtrate was concentrated under reduced pressure to constant weight to give 24 g of pale yellow solid, crude yield of two steps 107%.
EXAMPLE 4 preparation of 2-trifluoromethyl-4-hydroxypyrimidine (II)
To the reaction flask was added 40mL of hydrobromic acid, and 27.2 g of 4-methoxy-2-trifluoromethylpyrimidine was added with stirring. Heating to 60-70 ℃, stirring for 5 hours, cooling to 25-35 ℃ after the intermediate control reaction is qualified, filtering, dropwise adding a sodium hydroxide solution into the filtrate to adjust the pH to be = 2-3, separating out a solid, cooling to 5-10 ℃, stirring, filtering, drying a filter cake to constant weight, and obtaining 16.1 g of white powder solid, 95.9% of HPLC (high performance liquid chromatography), and the yield of 65.6%.
EXAMPLE 5 preparation of 4-chloro-2-trifluoromethylpyrimidine (I)
Adding 10 g of phosphorus oxychloride into a reaction bottle, stirring, adding 3.5 g of 2-trifluoromethyl-4-hydroxypyrimidine, and dropwise adding 2.2 g of triethylamine at 20-30 ℃. Heating to 100-105 ℃, stirring and reacting for 3 hours, cooling the reaction liquid to 0-5 ℃ after the intermediate control reaction is qualified, slowly dripping the reaction liquid into ice water, and stirring for 30 minutes at controlled temperature. Adding dichloromethane for extraction, standing for layering, adding dichloromethane into the water phase for extraction once, combining the organic phases, washing, and concentrating under reduced pressure to constant weight to obtain 3.4 g of brown yellow liquid, wherein the HPLC content is 97.9%, and the yield is 87%.
Finally, the above embodiments are only for illustrating the technical solutions of the present invention and not for limiting, although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions may be made to the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention, and all of them should be covered in the claims of the present invention.

Claims (10)

1. A process for the preparation of a compound of formula I,
Figure FDF0000011000030000011
the method is characterized by comprising the following steps:
a) reacting the compound shown in the formula V with sodium methoxide to prepare a reaction solution containing the compound shown in the formula IV; carrying out catalytic hydrogenation on a reaction liquid containing a compound shown in a formula IV to prepare a compound shown in a formula III;
Figure FDF0000011000030000012
b) the compound of the formula III is subjected to demethylation reaction to prepare a compound of a formula II;
Figure FDF0000011000030000013
c) halogenating the compound of formula II in the presence of a halogenating agent to obtain a compound of formula I,
d) preparing a compound VI from a compound shown in a formula VII and methyl trifluoroacetate in the presence of a condensing agent;
Figure FDF0000011000030000014
e) reacting the compound VI with a halogenating agent to prepare a compound V;
Figure FDF0000011000030000015
the compound shown in the formula V in the step a) reacts with sodium methoxide at the temperature of 30-35 ℃, and a reagent used in demethylation reaction in the step b) is hydrobromic acid.
2. The process according to claim 1, wherein the molar ratio of the amounts of sodium methoxide and compound of formula V used in step a) is: 1.15-1: 1.
3. The process according to claim 2, wherein the molar ratio of the amounts of sodium methoxide and compound of formula V is preferably: 1.05:1.
4. The process of claim 1, wherein the catalyst used for the catalytic hydrogenation in step a) is Pd/C.
5. The process of claim 1 wherein the halogenating agent in step c) is POCl 3.
6. The process according to claim 1, wherein the condensing agent in step d) is sodium methoxide.
7. The process according to claim 1, wherein the molar ratio of sodium methoxide to compound of formula VII is 2-3: 1.
8. The process according to claim 1, wherein the molar ratio of sodium methoxide to VII compound is preferably 2.2: 1.
9. The process of claim 1, the halogenating agent in step e) being POCl 3.
10. The process of claim 1, wherein triethylamine is added as a base in step e).
CN201510935307.5A 2015-12-15 2015-12-15 Preparation method of 4-chloro-2-trifluoromethylpyrimidine Active CN106883185B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510935307.5A CN106883185B (en) 2015-12-15 2015-12-15 Preparation method of 4-chloro-2-trifluoromethylpyrimidine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510935307.5A CN106883185B (en) 2015-12-15 2015-12-15 Preparation method of 4-chloro-2-trifluoromethylpyrimidine

Publications (2)

Publication Number Publication Date
CN106883185A CN106883185A (en) 2017-06-23
CN106883185B true CN106883185B (en) 2021-07-09

Family

ID=59174341

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510935307.5A Active CN106883185B (en) 2015-12-15 2015-12-15 Preparation method of 4-chloro-2-trifluoromethylpyrimidine

Country Status (1)

Country Link
CN (1) CN106883185B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113896679B (en) * 2021-11-18 2024-03-01 合肥利夫生物科技有限公司 Synthesis method of key intermediate of pyrrole pyridine kinase inhibitor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1051175A (en) * 1989-10-27 1991-05-08 布里斯托尔-迈尔斯斯奎布公司 1-[[1-[2-(trifluoromethyl)-4-pyrimidyl]-the 4-piperidyl] methyl]-large-scale producing method of 2-Pyrrolidone
WO2002076983A1 (en) * 2001-03-23 2002-10-03 Merck Sharp & Dohme Limited Imidazo-pyrimidine derivatives as ligands for gaba receptors
CN101389622A (en) * 2006-01-20 2009-03-18 诺瓦提斯公司 Pyrimidine derivatives used as pi-3 kinase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1051175A (en) * 1989-10-27 1991-05-08 布里斯托尔-迈尔斯斯奎布公司 1-[[1-[2-(trifluoromethyl)-4-pyrimidyl]-the 4-piperidyl] methyl]-large-scale producing method of 2-Pyrrolidone
WO2002076983A1 (en) * 2001-03-23 2002-10-03 Merck Sharp & Dohme Limited Imidazo-pyrimidine derivatives as ligands for gaba receptors
CN101389622A (en) * 2006-01-20 2009-03-18 诺瓦提斯公司 Pyrimidine derivatives used as pi-3 kinase inhibitors

Also Published As

Publication number Publication date
CN106883185A (en) 2017-06-23

Similar Documents

Publication Publication Date Title
CN104945332B (en) The preparation method of Erlotinib
CN102079737A (en) Method for preparing apigenin
CN111087394A (en) Synthetic method of 2, 9-substituted 4-halo-1, 10-phenanthroline
CN107098822A (en) A kind of preparation method for preparing the hydroxy acetophenone of 3 amino of Pranlukast key intermediate 2
CN112441875A (en) Method for copper photocatalytic synthesis of 9-trifluoromethyl-9, 10-dihydrophenanthrene compound
CN106883185B (en) Preparation method of 4-chloro-2-trifluoromethylpyrimidine
CN103980188B (en) The synthetic method of a kind of pyrrole Lun Panai and the synthetic method of intermediate and intermediate thereof
CN102690239A (en) Synthesis method of 1, 5-benzodiazepine derivative
CN102558054A (en) Process for preparing 3,4-dimethylpyrazole phosphate
CN116496223A (en) Preparation method of 5-bromo-4-methyl-2-trifluoromethyl pyrimidine
CN104844593A (en) Synthetic method for Apixaban drug intermediate
CN102267983B (en) Sym-triazine derivative compounds containing sym-tetrazine rings and preparation method thereof
CN104311485A (en) Preparation method of medicine bosutinib for treating leukemia
CN104693025B (en) A kind of method preparing 1,3-propanedicarboxylic acid list L-menthyl ester
CN108997229B (en) 1,2,3, 4-tetrahydroquinoxaline-6-carboxylic acid methyl ester and preparation method thereof
CN110183453B (en) Method for preparing 3-phenyl- [1,2,4] triazolo [4,3-a ] pyridine compound under catalysis of no metal
CN105001163B (en) A kind of synthetic method of four substituted imidazoles
CN101555248B (en) Method for preparing poly-substituted 1, 5-naphthyridine compound
CN102911123A (en) Preparation method of 2-chloro trifluoromethyl pyrimidine compound
CN110194760B (en) Process for preparing 3-benzylidene-2- (7' -quinoline) -2, 3-dihydro-isoindol-1-ones
CN105153211B (en) Method for synthesis of 1-(N-Boc-4-piperidine)-4-pyrazoleboronic acid pinaol ester
CN110642770B (en) Preparation method of 5-methoxyindole
CN103848773B (en) A kind of method preparing two indyl fluorene derivatives
CN102875344A (en) Method for preparing 2, 3, 4-trimethoxybenzaldehyde
CN112266360B (en) Synthesis method of high-purity histamine dihydrochloride

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant